Laura De Luca

Dr. Laura De Luca

orcid
University of Messina - Ophthalmology Department - Ocular On...

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LBLoredana Bergandi
Loredana Bergandi
GPGiulia Palladino
Giulia Palladino
AMAlessandro Meduri
Alessandro Meduri
Laura De LucaLaura De Luca
Laura De Luca
Francesca SilvagnoFrancesca Silvagno
Francesca Silvagno
Age-related macular degeneration (AMD) is strictly linked to chronic oxidative stress, inflammation, loss of epithelial barrier integrity, and often with abnormal new blood vessel development. In this study, the retinal epithelial cell line ARPE-19 was treated with pro-inflammatory transforming growth factor-beta (TGF-β) to investigate the activity of vitamin D (VD) and sulforaphane (SF) in abating the consequences of oxidative stress and inflammation. The administration of VD and SF lowered reactive oxygen species (ROS) levels, and abated the related expression of the pro-inflammatory cytokines interleukin-6 and interleukin-8 induced by TGF-β. We evaluated mitochondrial respiration as a source of ROS production, and we discovered that the increased transcription of respiratory elements triggered by TGF-β was prevented by VD and SF. In this model of inflamed epithelium, the treatment with VD and SF also reduced the secretion of VEGF, a key angiogenic factor, and restored the markers of epithelial integrity. Remarkably, all the observed biological effects were potentiated by the co-stimulation with the two compounds and were not mediated by VD receptor expression but rather by the ERK 1/2 pathway. Altogether, the results of this study reveal the powerful synergistic anti-inflammatory activity of SF and VD and lay the foundation for future clinical assessment of their efficacy in AMD.

28 February 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
MCMatteo Mario Carlà
Matteo Mario Carlà
GGGloria Gambini
Gloria Gambini
FGFederico Giannuzzi
Federico Giannuzzi
FBFrancesco Boselli
Francesco Boselli
Laura De LucaLaura De Luca
Laura De Luca
SRStanislao Rizzo
Stanislao Rizzo
Background: This study’s aim is to assess ChatGPT’s capability to analyze detailed case descriptions in glaucomatous patients and suggest the best possible surgical treatment. Methods: We conducted a retrospective analysis of 60 medical records of surgical glaucoma cases, divided into “ordinary” cases (n = 40) and “challenging” cases (n = 20). We entered every case description into ChatGPT-3.5’s interface and inquired “What kind of surgery would you perform?”. The frequency of accurate surgical choices made by ChatGPT, compared to those reported in patients’ files, was reported. Furthermore, we assessed the level of agreement with three senior glaucoma surgeons, asked to analyze the same 60 cases and outline their surgical choices. Results: Overall, ChatGPT surgical choices were consistent with those reported in patients’ files in 47/60 cases (78%). When comparing ChatGPT choices with the three glaucoma specialists, levels of agreement were 75%, 70%, and 83%, respectively. In ordinary cases, we did not report any significant differences when comparing ChatGPT answers with those of the three glaucoma specialists, when both of them were matched with patients’ files (p > 0.05 for all). ChatGPT’s performances were lower in “challenging” cases: when compared to patients’ files, the accuracy was 13/20 (65%); when compared to glaucoma specialists, the level of agreement was 50%, 40%, and 70%, respectively. Conclusion: In ordinary conditions, ChatGPT was able to propose coherent personalized treatment plans, and its performance was comparable to that of skilled glaucoma specialists but showed its limitations in the evaluation of more complex cases.

21 February 2024 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
GOGiovanni William Oliverio
Giovanni William Oliverio
AMAlessandro Meduri
Alessandro Meduri
VBValentina Urzì Brancati
Valentina Urzì Brancati
IIIrene Ingrande
Irene Ingrande
Laura De LucaLaura De Luca
Laura De Luca
PAPasquale Aragona
Pasquale Aragona
Purpose: Aim of the study was to evaluate the efficacy of dexamethasone (DEX) 0.7 mg intravitreal implant in patients with diabetic macular edema (DME) and serous retinal detachment (SRD), and to study the prognostic factors on a follow up of 12 months. Methods: Forty eyes of twenty- six patients with centre involving DME and SRD, who underwent DEX implant, were enrolled. Best-corrected visual acuity (BCVA), Swept source OCT imaging and intraocular pressure were evaluated. Central macular thickness (CMT), vitreomacular adhesion (VMA), disorganization of retinal inner layers (DRILs), hyperreflective dots (HRD), SRD and ellipsoid zone (EZ) disruption were included in the analysis at baseline and 12 months after implant. Results: According to our parametric analysis, at 12 months, BVCA improvement from 48.6 ± 23.4 letters to 53.3 ± 24.5 letters was statistically significant ( p = 0.04), CMT decreased from 460 ± 99.52 μm to 322.9 ± 117 μm. The presence at baseline of VMA ( p = 0.01), EZ disruption ( p = 0.03) and DRILs ( p = 0.04), were associated with poor BCVA improvement at the end of follow-up. Conclusion: In conclusion, OCT biomarkers can be considered significant prognostic factors for treatment outcome in patients with DME undergoing DEX intravitreal implant.

1 June 2025 in Retina
Verified
Journal Article
Open access
AMAlessandro Meduri
Alessandro Meduri
Laura De LucaLaura De Luca
Laura De Luca
GOGiovanni William Oliverio
Giovanni William Oliverio
MMMaura Mancini
Maura Mancini
LMLetteria Minutoli
Letteria Minutoli
PAPasquale Aragona
Pasquale Aragona
Purpose: This literature review synthetizes current evidence on the timing and efficacy of dexamethasone intravitreal injections for diabetic macular edema in patients undergoing cataract surgery, particularly phacoemulsification, to determine the optimal timing for improved outcome. Methods: A systematic review of the literature was conducted across key databases to identify peer-reviewed studies, clinical trials, and meta-analyses addressing dexamethasone injections administered pre-, intra-, and postoperatively for diabetic macular edema in the context of cataract surgery. Studies were selected based on relevance to timing, visual outcomes, and inflammation control, with a focus on comparative efficacy. Results: The findings suggest that timely dexamethasone injections can substantially reduce inflammation and enhance visual recovery for patients with diabetic macular edema undergoing cataract surgery. Studies indicate that preoperative injections may effectively dampen the inflammatory response triggered by surgical trauma, potentially preserving retinal integrity, whereas intraoperative and postoperative administrations contribute to sustained anti-inflammatory effects during the recovery phase. Comparative studies also highlight dexamethasone's advantages over other anti-inflammatory treatments, such as NSAIDs, particularly in preventing cystoid macular edema. Notably, there was considerable variation in dosage and timing across studies, underscoring the need for standardized treatment protocols. Conclusion: Dexamethasone intravitreal injections offer a valuable intervention for managing diabetic macular edema in diabetic patients undergoing cataract surgery, with optimal timing playing a crucial role in maximizing therapeutic benefits. Preoperative injections appear to be particularly beneficial in reducing the risk of postoperative inflammatory complications. Further research should focus on developing comprehensive guidelines for timing and dosage to standardize treatment and improve patient outcomes in this high-risk population.

22 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Laura De LucaLaura De Luca
Laura De Luca
GOGiovanni William Oliverio
Giovanni William Oliverio
MMMaura Mancini
Maura Mancini
Rino FrisinaRino Frisina
Rino Frisina
Feliciana MennaFeliciana Menna
Feliciana Menna
AMAlessandro Meduri
Alessandro Meduri
Background: Scleral fixation of intraocular lenses (IOLs) is a valuable option in cases of aphakia or inadequate capsular support, yet conventional sutured and sutureless approaches can pose technical challenges and complication risks. The needle-guided scleral fixation technique offers a simplified, single-suture solution that enhances safety and reproducibility. Methods: In this retrospective interventional case series, 30 eyes with insufficient capsular support underwent IOL implantation using Meduri’s needle-guided single-suture technique at the G. Martino University Hospital, Messina. The surgical method employs a 24-gauge needle to guide a double-armed 10-0 polypropylene suture through the sclera for precise IOL anchorage, minimizing vitreous manipulation. Outcomes were assessed over 24 months, including best-corrected visual acuity (BCVA), IOL centration, intraocular pressure (IOP), and postoperative complications. Results: Mean BCVA improved from X to Y LogMAR at two years (p < 0.05). All IOLs remained well-centered without tilt or decentration. Mild conjunctival hyperemia occurred in 70% of cases, resolving spontaneously. No suture erosion, vitreous hemorrhage, or retinal detachment was observed. Conclusions: The needle-guided single-suture technique provides a stable, efficient, and reproducible method for posterior chamber IOL fixation in aphakic eyes lacking capsular support. Its minimal learning curve and reduced surgical complexity make it an attractive alternative to both traditional sutured and modern sutureless methods, particularly in centers without vitreoretinal expertise.

Verified
Journal Article
Open access
PDF file
Feliciana MennaFeliciana Menna
Feliciana Menna
SLStefano Lupo
Stefano Lupo
Laura De LucaLaura De Luca
Laura De Luca
ABAntonio BALDASCINO
Antonio BALDASCINO
EVEnzo Maria Vingolo
Enzo Maria Vingolo
AMAlessandro Meduri
Alessandro Meduri
Mitochondrial dysfunction and oxidative stress are increasingly recognized as key contributors to the development and progression of retinal degenerative diseases, including age-related macular degeneration and inherited retinal dystrophies. Growing evidence suggests that alterations in mitochondrial function, excessive production of reactive oxygen species, defective mitophagy, and chronic inflammatory responses are closely interconnected processes that contribute to retinal cell damage and degeneration. This review provides an overview of the current understanding of the molecular mechanisms linking mitochondrial dysfunction to retinal degeneration, with particular emphasis on the impact of oxidative stress, mitochondrial quality-control pathways, and inflammatory signaling. Available evidence indicates that mitochondrial DNA damage, impaired bioenergetics, and dysregulated mitochondrial dynamics play a crucial role in the degeneration of photoreceptors and retinal pigment epithelium cells. In turn, oxidative stress further exacerbates mitochondrial impairment, creating a self-sustaining cycle that promotes disease progression. Recent advances have also highlighted the therapeutic potential of targeting mitochondrial pathways. Although several mitochondria-directed strategies have shown encouraging results in experimental models, their translation into clinical practice remains at an early stage. Overall, the available data identify mitochondria as a promising therapeutic target and support the development of precision medicine approaches aimed at preserving retinal function and slowing disease progression in patients with retinal degenerative disorders.